Article 3: Global Health Governance
Why in News: Recent institutional instability and policy shifts in the US Food and Drug Administration have raised concerns over excessive global dependence on a single regulatory authority.
Key Details
- The FDA has long acted as a global benchmark regulator for drugs, vaccines, and medical devices.
- Many countries rely on FDA approvals through accelerated or reliance-based regulatory pathways.
- Recent issues like leadership turnover and policy changes have created uncertainty globally.
- Countries like India are now focusing on strengthening domestic regulatory capacity.
FDA as Global Regulatory Benchmark
- Gold Standard Regulator: The FDA is globally regarded as a highly credible authority, setting standards for drug safety, efficacy, and quality, influencing regulators worldwide.
- Wide Scope of Regulation: It regulates pharmaceuticals, biologics, vaccines, medical devices, and diagnostics, making it central to global healthcare innovation.
- Global Influence: Regulatory bodies across Asia, Africa, and Latin America often align their standards with FDA guidelines to maintain international credibility.
- Market Access Significance: FDA approval is crucial for companies as the US is the largest pharmaceutical market, influencing global commercialization strategies.
Reliance-Based Regulatory Systems
- Accelerated Approval Pathways: Many countries adopt reliance models, where they partially depend on FDA or EMA decisions to speed up approvals.
- Efficiency for Developing Nations: This reduces regulatory burden for countries with limited capacity, ensuring faster access to life-saving drugs and vaccines.
- Global Regulatory Harmonisation: Reliance systems promote uniform safety standards, improving trust in medical products across borders.
- Risks of Overdependence: Any delay or change in FDA processes can create cascading delays in multiple countries simultaneously.
Impact on Clinical Trials and Innovation
- Standardisation of Clinical Trials: FDA-approved protocols influence trial design, endpoints, and safety norms globally.
- Pharmaceutical Industry Alignment: Companies design trials to meet FDA requirements to ensure global market acceptance.
- Emerging Technologies Regulation: FDA policies on AI in healthcare, digital health tools, and gene therapy shape innovation trends worldwide.
- Research Ecosystem Dependence: Changes in FDA expectations can alter global R&D investments and innovation pathways.
Recent Challenges within FDA
- Leadership Instability: Frequent changes in leadership, especially in biologics divisions, create uncertainty in regulatory priorities.
- Budgetary and Political Pressures: Funding constraints and policy debates have impacted decision-making efficiency.
- Controversial Approvals: Some recent drug approvals have raised concerns regarding transparency and scientific rigour.
- Impact on Global Systems: These issues create ripple effects in countries dependent on FDA decisions, affecting drug availability timelines.
India’s Regulatory Framework and Challenges
- Role of CDSCO: Central Drugs Standard Control Organisation is India’s primary regulator responsible for drug approvals and safety.
- Growing Pharmaceutical Sector: India is known as the “pharmacy of the world”, supplying over 60% of global vaccines and a large share of generic medicines.
- Dependence on Global Benchmarks: Despite improvements, India often refers to FDA or EMA approvals for regulatory validation.
- Need for Capacity Building: Strengthening regulatory science, infrastructure, and manpower remains essential for self-reliance.
Need for Multipolar Global Health Governance
- Diversification of Regulatory Authority: Reducing dependence on a single regulator ensures resilience and stability in global health systems.
- Role of WHO and Global Mechanisms: World Health Organization initiatives like prequalification programmes support global quality assurance.
- Regional Cooperation Models: Platforms like African Medicines Agency (AMA) and regional harmonisation efforts promote collective regulatory strength.
- Equity in Global Health: A multipolar system ensures fair access to medicines, especially for low- and middle-income countries.
Implications for India
- Atmanirbhar Bharat in Healthcare: Strengthening domestic regulation aligns with India’s goal of self-reliance in pharmaceuticals.
- Strategic Global Positioning: India can emerge as a regulatory leader in the Global South.
- Public Health Security: Robust national systems reduce vulnerability to external regulatory shocks.
- Policy Reforms Needed: Emphasis on transparency, digitalisation, and skilled manpower is essential.
Conclusion
Global health governance must evolve from FDA-centric dependence to a multipolar regulatory framework. Strengthening national regulators like CDSCO, promoting regional cooperation, and enhancing global institutional mechanisms will ensure equitable, efficient, and resilient healthcare systems. For India, this is both a challenge and an opportunity to emerge as a global leader in pharmaceutical regulation.
EXPECTED QUESTIONS FOR UPSC CSE
Prelims MCQ
Q. Which of the following best describes “reliance-based regulatory pathways”?
(a) Independent drug approval without external reference
(b) Partial reliance on decisions of trusted global regulators
(c) Exclusive WHO-based approvals
(d) Trade-based pharmaceutical approvals
Answer: (b)
Descriptive Question
Q. “Overdependence on a single regulatory authority like the FDA can undermine global health governance.” Discuss with reference to India. (150 Words, 10 Marks)